QLS1304 / Qilu Pharma - LARVOL DELTA

Phase Ib/II Clinical Study of QLS1304 Combined With Endocrine Therapy in the Treatment of ER+/HER2- Breast Cancer Patients (clinicaltrials.gov) - P1/2 | N=300 | Not yet recruiting | Sponsor: Qilu Pharmaceutical Co., Ltd.

New P1/2 trial • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Oncology • Solid Tumor

QLS1304, a highly potent and selective KAT6A/B inhibitor treating ER+HER2- breast cancer (AACR 2025) - "Collectively, QLS1304 appears to be a promising candidate for the treatment of ER+HER2- breast cancer given its efficacy in both SoC-sensitive and SoC-resistant models. Moving it forward into clinical trials is warranted both as single agent and combining with other therapies."

Breast Cancer • Estrogen Receptor Positive Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • ER • HER-2 • KAT6A • KAT6B • KAT8

Phase I Clinical Study of QLS-1304 in the Treatment of Patients With Advanced Malignant Tumors (clinicaltrials.gov) - P1 | N=180 | Not yet recruiting | Sponsor: Qilu Pharmaceutical Co., Ltd.

New P1 trial • Oncology • Solid Tumor